Compare HTO & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HTO | MLYS |
|---|---|---|
| Founded | 1985 | 2019 |
| Country | United States | United States |
| Employees | 837 | N/A |
| Industry | Water Supply | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.1B |
| IPO Year | N/A | 2023 |
| Metric | HTO | MLYS |
|---|---|---|
| Price | $66.84 | $26.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | ★ $62.00 | $48.67 |
| AVG Volume (30 Days) | 477.0K | ★ 916.3K |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.05% | N/A |
| EPS Growth | N/A | ★ 37.43 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $10.26 | N/A |
| Revenue Next Year | $7.06 | N/A |
| P/E Ratio | $17.19 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $43.75 | $12.59 |
| 52 Week High | $66.05 | $47.65 |
| Indicator | HTO | MLYS |
|---|---|---|
| Relative Strength Index (RSI) | 71.56 | 46.19 |
| Support Level | $55.76 | $26.01 |
| Resistance Level | N/A | $31.26 |
| Average True Range (ATR) | 1.34 | 1.20 |
| MACD | 0.06 | -0.14 |
| Stochastic Oscillator | 88.70 | 15.52 |
H2O America is a national investor-owned network of local water and wastewater utilities united by one purpose: delivering clean, high-quality water to the communities it calls home. Across approximately 407,000 water and wastewater service connections, the company invests in critical infrastructure to strengthen the water supply for generations to come. Its single reportable segment provides water utility and utility-related services to its customers.
Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.